Literature DB >> 12084338

What does prostate-specific antigen recurrence mean?

C R Pound1, A W Partin.   

Abstract

The return of the prostate-specific antigen (PSA) to a detectable serum level (PSA recurrence) is usually the first sign of recurrent disease after radical prostatectomy. PSA recurrence generally occurs in men who are otherwise asymptomatic and may occur as late as 5 to 10 years after surgery. Men in this situation want to know what this means regarding the likelihood of clinical disease recurrence and, ultimately, survival. An evaluation for recurrent disease is warranted but generally does not reveal objective signs of clinical disease in the majority of men. Although select men may benefit from salvage local therapy, a PSA recurrence is most often an early sign of distant disease present since the time of surgery. The decision whether or not to initiate systemic therapy in these men is difficult and controversial. Fortunately, recent developments in determining the significance of a PSA recurrence may help the patient and his physician to make a more informed decision regarding treatment options.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12084338     DOI: 10.1007/s11934-000-0032-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  59 in total

1.  Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy.

Authors:  J A Cadeddu; A W Partin; J I Epstein; P C Walsh
Journal:  Urology       Date:  1997-08       Impact factor: 2.649

2.  Correlation of margin status and extraprostatic extension with progression of prostate carcinoma.

Authors:  L Cheng; M F Darson; E J Bergstralh; J Slezak; R P Myers; D G Bostwick
Journal:  Cancer       Date:  1999-11-01       Impact factor: 6.860

3.  Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.

Authors:  M A Seltzer; Z Barbaric; A Belldegrun; J Naitoh; F Dorey; M E Phelps; S S Gambhir; C K Hoh
Journal:  J Urol       Date:  1999-10       Impact factor: 7.450

4.  Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results.

Authors:  F M Jhaveri; C D Zippe; E A Klein; P A Kupelian
Journal:  Urology       Date:  1999-11       Impact factor: 2.649

5.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.

Authors:  J A Cadeddu; A W Partin; T L DeWeese; P C Walsh
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

6.  Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns.

Authors:  D M Nudell; G D Grossfeld; V K Weinberg; M Roach; P R Carroll
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

7.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.

Authors:  C R Pound; A W Partin; J I Epstein; P C Walsh
Journal:  Urol Clin North Am       Date:  1997-05       Impact factor: 2.241

8.  Recurrent prostate cancer despite undetectable prostate specific antigen.

Authors:  T K Takayama; J N Krieger; L D True; P H Lange
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

9.  Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.

Authors:  S M Eulau; D J Tate; T A Stamey; M A Bagshaw; S L Hancock
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-07-01       Impact factor: 7.038

10.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Authors:  M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.